Category: Personal Finance

1. SBI Small Cap Fund:

The small cap fund from the house of SBI mutual fund was launched in September 2009 and aims to offer investors with avenues of long term capital growth by investing mainly in a well-diversified portfolio of small cap stocks.

Since inception the fund has yielded returns to the tune of 20.48%. Furthermore, the fund commands a sizable asset size of Rs. 9620 crore as on July 31, 2021 i.e. 46% of investment in the category. Expense ratio of the fund is 1.93% as on June 30, 2021.

For its performance, the fund tracks the benchmark S&P BSE Small Cap TRI. Over a 1-year period, the scheme has underperformed the benchmark with return of over 70%. NAV of the fund as on August 11, 2021 was 92.2625.

SIP in the fund can be started for Rs. 500, while for lump sum investment you need to put in a minimum of Rs. 5000.

Top holdings of the fund are Elgi Equipments, Carborundum, JK Cement, Sheela Foam, V-Guard Industries, Finolex Industries etc.

Notably, Value Research has accorded this scheme 4-Star rating.

2. Nippon India Small Cap Fund:

In existence since September 2010, this fund has assets under management of Rs. 16,613 crore (as on July 31, 2021). Expense ratio of the fund is higher than the category average at 1.98%. Despite being a small cap fund, the mutual fund risk-o-meter has classified the fund as moderately high on risk. Latest NAV of the fund is 75.0851. Since its launch the fund has offered return of 20.30%.

The scheme is benchmarked against NIFTY Smallcap 250 TRI and over a 1-year period has yielded return of 94.28%.

The scheme other than offering long term capital appreciation also works with the objective of generating consistent returns by investing in debt and money market instruments.

SIP in the plan can be initiated with a minimum of Rs. 100 and for lump sum investment investors need to put in Rs. 5000.

Top stocks in the fund’s portfolio include Deepak Nitrite, Birla Corp, Navin Fluorine, Balrampur Chini Mills, Tube Investments, Bajaj Electricals etc.

3. Mirae Asset Emerging Bluechip Fund:

It is a large and mid cap fund from the stable of Mirae Asset Mutual fund. The fund attracts over 20% of the investment into the category and its asset size as of July 31, 2021 is Rs. 19,568 crore. Expense ratio of the fund is 1.67% lower than the category average. The fund as per the risk-o-meter is placed under the high risk category.Latest NAV of the fund is 91.796.

The fund is in existence since July 2010 and tracks its return based on the benchmark NIFTY Large Midcap 250 TRI. The fund since launch has offered return of 22.11%. The fund gives investors a chance to participate in the growth of emerging companies that show the potential to become tomorrow’s blue-chips.

The fund employs bottoms up approach of investment: driven by value investing, in growth oriented businesses.

SIP in the fund can be kick-started for minimum of Rs. 1000. Also there applies an exit load in a case when the units are redeemed within 1 year of 1%.

The fund is parked 35-65% in large cap stocks and 35-65% in mid cap stocks. Top holdings of the fund include stocks like ICICI Bank, HDFC Bank, Infosys, Axis Bank, SBI, Bharti Airtel, JK Cement, Mphasis and Tata Steel among others.

4. Quant Tax Plan-G:

It is an ELSS or equity linked savings scheme from the house of Quant Mutual fund. NAV of the fund as on August 11, 2021 is 203.6. The fund is a very high risk plan and commands a fund size of Rs. 327 crore as on July 31, 2021. Expense ratio of the fund is 2.25%, slightly on the higher side in comparison to category average.

The fund is a 21 year old plan, in existence since and since launch has offered return of over 15%. The fund for analyzing performance is benchmarked against Nifty 50 TRI.

SIP as well a lump sum investment into the ELSS scheme by Quant can be started with an investment as low as Rs. 500. Being an ELSS, this has a lock-in period of 3 years. The fund has no exit load charges.

Other than capital appreciation through investment in a well diversified basket of equities, the fund also looks to supplement this income by giving out possible dividend and other income.

Top stocks in Quant Tax Plan include ITC, Indiabulls Real Estate, Vedanta, Aurobindo Pharma, RIL, Sun Pharma, ICICI Securities, Stylam Industries etc.

5. DSP Small Cap Fund

The fund is a 14-year old scheme being run by DSP Mutual fund. The asset size of the fund is Rs. 8266 crore as of July 31, while it charges an expense ratio equal to 1.9% as on June 30. NAV of the fund is 98.67 as on August 11.

The primary objective with which the scheme is in place is to generate long term capital appreciation from investment majorly in equity and equity related securities of small cap companies. Also, on a time to time basis, the fund would deploy money in other equity and equity related securities to realize optimal portfolio

The scheme is bench-marked against S&P BSE Small Cap TRI and since inception has yielded return of over 17%.

SIP as well as lump sum investment in the fund can be started for Rs. 500.

Top holdings of the fund’s portfolio comprise stocks like Nilkamal, Atul, KPR Mill, IPCA and Suprajit Engineering among others.

Top 5 Equity Mutual Funds Based On 10-Year SIP Returns

Conclusion:

The equity mutual fund investments made for over a longer term are able to offset any major downsides during the course of the investment. Also, the above story that revolves around top performing equity funds based on 10-year SIP returns includes 3 small caps which may not be the suitable investment category for most mutual fund investors being extremely high on risk. These are typically high risk and high return schemes. Nevertheless the 2-other funds from the large and mid-cap space and ELSS can be added by most investor classes.

Disclaimer:

Mutual fund investments are subject to risk being linked to equity markets and debt securities. Also, note the above story is just for informational purpose and should be construed as investment advice into these mutual funds.

GoodReturns.in

5 Best Flexi Cap Mutual Funds Ranked By CRISIL

PGIM India Flexi Cap Fund

PGIM India Flexi Cap Fund Direct-Growth is a PGIM India Mutual Fund Multi-Cap mutual fund scheme. The assets under management (AUM) of PGIM India Flexi Cap Fund Direct-Growth is $1,689 crores. The fund’s expense ratio is 0.3 percent, which is lower than the expense ratios charged by most other Multi Cap funds.

The 1-year returns on PGIM India Flexi Cap Fund Direct-Growth are 67.76 percent. It has had an average yearly return of 17.09 percent since its inception. The Technology, Healthcare, Financial, Construction, and Chemicals sectors account for the majority of the fund’s holdings. To begin a SIP in this fund, a minimum monthly commitment of Rs 1000 is required.

The fund is ranked number 1 by CRISIL rating agency.

UTI Flexicap

UTI Mutual Fund’s UTI Flexi Cap Fund Direct-Growth is a Multi Cap mutual fund program. UTI Flexi Cap Fund Direct-Growth manages assets of Rs. 20,922 crores (AUM). The fund’s expense ratio is 1.19 percent, which is higher than the expense ratios charged by most other Multi Cap funds.

The 1-year returns on UTI Flexi Cap Fund Direct-Growth are 61.66 percent. It has had an average yearly return of 17.57 percent since its inception. The fund’s top 5 holdings are in Bajaj Finance Ltd., HDFC Bank Ltd., Larsen & Toubro Infotech Ltd., Kotak Mahindra Bank Ltd., Housing Development Finance Corpn. Ltd.

The fund is benchmarked against Nifty 500 TRI. The NAV of UTI Flexi Cap Fund for Aug 10, 2021 is 255.33.

The fund is ranked number 1 by CRISIL rating agency.

Canara Robeco Flexi Cap Fund

Canara Robeco Flexi Cap Fund Direct-Growth is a Canara Robeco Mutual Fund Multi-Cap mutual fund plan. Canara Robeco Flexi Cap Fund Direct-Growth manages a total of 5,185 crores in assets (AUM). The fund’s expense ratio is 0.6 percent, which is lower than the expense ratios charged by most other Multi Cap funds.

Canara Robeco Flexi Cap Fund Direct-Growth returns have been 50.30 percent during the last year. It has returned an average of 15.70 percent every year since its inception. The portfolio of the Scheme is made up of 46 securities, with the top ten underlying securities accounting for 51% of the net assets.

The fund is ranked number 2 by CRISIL rating agency.

DSP Flexi Cap Fund

DSP Mutual Fund’s DSP Flexi Cap Fund Direct Plan-Growth is a Multi Cap mutual fund strategy. DSP Flexi Cap Fund Direct Plan-Growth manages a total of 5,985 crores in assets (AUM). The fund’s expense ratio is 0.94 percent, which is comparable to the expense ratios charged by most other Multi Cap funds.

DSP Flexi Cap Fund Direct Plan’s 1-year growth returns are 58.78 percent. It has had an average yearly return of 16.57 percent since its inception. The financial, construction, technology, automobile, and chemical industries account for the majority of the fund’s holdings. The NAV of DSP Flexi Cap Fund for Aug 10, 2021 is 68.07. ICICI Bank Ltd., HDFC Bank Ltd., Infosys Ltd., Ultratech Cement Ltd., and Bajaj Finance Ltd. are among the companies in which the DSP Flexi Cap Fund has placed the majority of its money.

The fund is ranked number 2 by CRISIL rating agency.

Union Flexi Cap

Union Mutual Fund’s Union Flexi Cap Fund-Growth is a Multi Cap mutual fund plan. Union Flexi Cap Fund-Growth manages assets worth a total of 645 crores (AUM). The fund’s expense ratio is 2.51%, which is greater than the expense ratios charged by most other Multi Cap funds.

Union Flexi Cap Fund’s 1-year growth returns are 53.86 percent. It has returned an average of 11.94 percent per year since its inception. The financial, technology, healthcare, automobile, and services sectors account for the majority of the fund’s holdings.

HDFC Bank Ltd., Infosys Ltd., ICICI Bank Ltd., Reliance Industries Ltd., and Muthoot Finance Ltd. are the fund’s top five holdings. Union Flexi Cap Fund’s NAV on August 10, 2021 is 31.51.

In line with the broader markets, pharma stocks have done reasonably well. The advent of Covid last year, has led to a select surge in pharma stocks, as healthcare is back in the limelight. Here are 2 pharma stocks that can generate good returns for investors according to broking firm, Emkay Global.

Lupin Ltd

Emkay Global has set a price target of Rs 1,300 on the stock of Lupin, which signifies a nearly 30% upside on the stock from its current market price of Rs 997.

Double-digit revenue growth guidance was maintained but margin guidance was lowered to 17- 18% in H2FY22 vs. 19-20% for FY22, Emkay Global has said.

“The US business was marred by price erosion in key products such as Famotidine, L-thyroxine and Metformin, failure to supply penalty related to Albuterol and transitioning to long-term contracts for Albuterol,” the brokerage has said.

Adjusted for one-time licensing fees, revenue/EBITDA/PAT missed Emkay’s estimates by 10%, 32% and 37%. The revenue miss was largely driven by substantial miss in the US revenue. EBITDA miss was driven by lower-than-expected GM and higher employee costs, offset by lower operational expenditure.

“We reiterate our Buy rating on the stock but cut our target price of Rs 1,300 from Rs 1,325 as we modestly lower our earnings estimates for FY22/23/24 to reflect the Q1 miss, leading to a lower US revenue base,” Emkay Global has said.

Cadila Healthcare

Emkay Global has set a target price of Rs 600 on the stock of Cadila Healthcare in the next 1-year, which is higher than the current market price of Rs 544.

“The management sounded confident of selling its limited vaccine supply (10-12mn/month) in the domestic market. We believe vaccine uptake beyond FY22 could be minimal. Hence, we reduce vaccine-related upside to Rs10 per share from Rs 50 per share.

Management reaffirmed the US launch expectation of 30+ products but expects low-single digit growth in FY22. Similarly, US growth in FY23 is also expected to be subdued. Growth in the US business will be driven by complex injectables and transdermal products,” the brokerage has said.

The management of Cadila expects US revenue growth in low-single digits in FY22. “While the company plans to launch 30 plus products in the US, generic entry into Asacol may keep the growth in check. Management is expecting 1-2 additional generic entries in Asacol. Even for FY23, US growth is expected to be muted. US growth is expected to pick up once inejctables and transdermal products are commercialized. We estimate a mid-single digit decline in FY22 and flat US revenue in FY23 as the basket of in-licensed products (24 in total, of which 5 will be monetized in FY23) might offset the decline in Asacol,” Emkay has said.

“We maintain Hold rating but reduce our target price to Rs 600 from Rs 640 as we lower the Covid vaccine upside. Our FY23/24E headline numbers are revised down meaningfully as we remove vaccine upside, but our core earnings estimates are maintained,” the brokerage has added.

Disclaimer

Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage houses are not liable for any losses caused as a result of decisions based on the article.